Metrics to compare | 298380 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship298380PeersSector | |
|---|---|---|---|---|
P/E Ratio | −155.0x | −17.4x | −0.3x | |
PEG Ratio | −2.23 | −0.30 | 0.00 | |
Price/Book | 20.7x | 2.1x | 2.6x | |
Price / LTM Sales | 41.4x | 6.8x | 3.0x | |
Upside (Analyst Target) | 289.2% | 51.8% | 56.7% | |
Fair Value Upside | Unlock | 16.8% | 9.4% | Unlock |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.